NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright

11 Sep 2026, 02:08 by Doug Wharley · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $52.00 target price on the stock.

NAMS has been the topic of several other reports. Royal Bank Of Canada lowered their target price on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. BMO Capital Markets began coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $49.73.

Read Our Latest Report on NAMS

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $21.86 on Tuesday. The company’s fifty day moving average price is $28.84 and its 200 day moving average price is $31.27. NewAmsterdam Pharma has a 1 year low of $21.80 and a 1 year high of $42.21. The company has a market capitalization of $2.61 billion, a PE ratio of -10.12 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. On average, equities analysts expect that NewAmsterdam Pharma will post -1.82 EPS for the current year.

Insider Buying and Selling

In related news, CAO Louise Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Johannes Kastelein sold 125,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. This trade represents a 64.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 271,600 shares of company stock worth $7,797,962 in the last 90 days. Insiders own 12.74% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of NewAmsterdam Pharma during the first quarter worth approximately $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in NewAmsterdam Pharma by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after purchasing an additional 34,563 shares in the last quarter. Geode Capital Management LLC lifted its holdings in NewAmsterdam Pharma by 15.9% in the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after purchasing an additional 13,629 shares in the last quarter. Legal & General Group Plc boosted its stake in NewAmsterdam Pharma by 33.5% during the 2nd quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock worth $801,000 after purchasing an additional 11,106 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in NewAmsterdam Pharma by 12.7% during the 2nd quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock worth $2,427,000 after purchasing an additional 15,101 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

More NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $52 price target. Other analysts also maintain positive views, including BMO Capital Markets at $58, Jefferies at $45 and RBC at $50, supporting the longer-term outlook for NAMS. HC Wainwright rating report
Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests short selling is not a meaningful explanation for the recent decline, although the data may reflect an incomplete or anomalous report. NewAmsterdam Pharma market data
Neutral Sentiment: Analyst reports discussing NAMS alongside Amgen, Dyne Therapeutics and Ionis Pharmaceuticals did not identify a new company-specific catalyst. Broader healthcare-sector commentary may influence sentiment but provides limited direct information about NewAmsterdam’s business. Healthcare analyst report
Negative Sentiment: Director John W. Smither sold 1,600 shares for approximately $40,512, reducing his direct holdings by 15.44%. Although the sale may have been for personal reasons, it can reinforce investor caution during a period of market weakness. SEC insider transaction filing
Negative Sentiment: NAMS reached a new one-year low following the insider-sale disclosure, signaling continued technical and investor-pressure concerns. The company also remains loss-making; its latest quarterly EPS missed expectations, and analysts forecast a full-year loss of about $1.82 per share. New one-year low report

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.